Improvement in quality of life for cancer patients treated with epoetin alfa.
Anaemia is a common complication of cancer and cancer therapies, and fatigue is one of the most common symptoms of anaemia, disrupting functional performance and reducing overall quality of life. The positive effects of treating renal patients with recombinant human erythropoietin are well documented. This case report series details the specific effects of fatigue on individual patients with cancer and their way of life, and describes their significant improvement in lifestyle following the reversal of anaemia using recombinant human erythropoietin, epoetin alfa.
Libretto
S E
SE
Janssen-Cilag Ltd, High Wycombe, Buckinghamshire, UK. slibrett@jacgb.jnj.com
Barrett-Lee
P J
PJ
Branson
K
K
Gorst
D W
DW
Kaczmarski
R
R
McAdam
K
K
Stevenson
P
P
Thomas
R
R
D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D011788:Quality of Life; D011994:Recombinant Proteins
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa